Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells
Hypoxia-inducing factor-1 alpha (HIF-1α), is a major survival factor for tumor cells growing in a low oxygen environment. The anti-cancer agent imexon binds thiols and causes accumulation of reactive oxygen species (ROS) in pancreatic cancer cells. Unlike many cytotoxic agents, imexon is equi-cytotoxic in human MiaPaCa-2 and Panc-1 cells grown in normoxic (21% O2) and hypoxic (1% O2) conditions. Western blot analyses of imexon-treated cells demonstrated that imexon reduces HIF-1α protein levels in both normoxic and hypoxic conditions in a time- and concentration-dependant fashion. Gemcitabine did not similarly affect HIF-1α levels. Imexon did not reduce transcription of new HIF-1α mRNA, but did reduce the synthesis of new proteins, including HIF-1α, measured by 35S methionine/cysteine (Met/Cys) incorporation. Concurrently, the half-life of existing HIF-1α protein was increased by imexon, in association with a marked inhibition of chymotryptic activity in the 20S proteasome. The inhibition of HIF-1α translation was not specific, rather it was part of a general decrease in protein translation caused by imexon. This inhibitory effect on translation did not involve phosphorylation of eukaryotic initiation factor-2α (eIF-2α) and was not closely correlated to cell growth inhibition by imexon, suggesting that mechanisms other than protein synthesis inhibition contribute to the drug’s cytotoxic effects. In summary, imexon blocks the translation of new proteins, including HIF-1α, and this effect overcomes an increase in the stability of preformed HIF-1α due to proteasome inhibition by imexon. Because net HIF-1α levels are reduced by imexon, combination studies with other drugs affected by HIF-1α survival signaling are warranted.
KeywordsHypoxia Imexon Normoxia Pancreas Protein synthesis
These studies were supported by grants CA17094 (RTD) and CA115626 (RTD) from the National Institutes of Health, Bethesda, MD.
- 2.Cohen SJ, Zalupski M, Modiano M, Conkling P, Patt Y, Davis P, Dorr R, Boytim M, Hersh E (2008) A phase I study of Amplimexon (AMP, imexon inj.) plus gemcitabine (Gem) as first line therapy in advanced pancreatic cancer (PC) with preclinical mechanistic study of dose limiting toxicity (DLT). Proceedings of the ASCO Annual MeetingGoogle Scholar
- 13.Poplin E, Levy DE, Berlin M (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). ASCO Proceedings 24(18s):180sGoogle Scholar
- 36.Shain KH, Landowski TH, Dalton WS (2002) Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 168:2544–2553PubMedGoogle Scholar
- 45.Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMedGoogle Scholar
- 46.Raijiman I, Levin B (1995) Exocrine tumors of pancreas. In: Haubrich WS, Schaffner F (eds) Bockus gastroentrology. 5th edn. Saunders, Philadelphia, pp 2984–3001Google Scholar